Prof. Miklos Pless
Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial
Uster A, Ruefenacht U, Ruehlin M, Pless M, Siano M, Haefner M, Imoberdorf R, Ballmer P. Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial. Nutrition 2013; 29:1342-9.
19.02.2013Influence of a nutritional intervention on dietary intake and quality of life in cancer patients: a randomized controlled trial
19.02.2013Nutrition 2013; 29:1342-9
Uster Alexandra, Ruefenacht Ursula, Ruehlin Maya, Pless Miklos, Siano Marco, Haefner Mark, Imoberdorf Reinhard, Ballmer Peter E
VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
Gautschi O, Stahel R, Carbone D, Na K, Hsu Schmitz S, Bubendorf L, Baty F, Brutsche M, Pless M, Zappa F, Roder J, Grigorieva J, Roder H, Peters S, Crowe S, Dingemans A, Smit E. VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528. Lung Cancer 2012; 79:59-64.
01.11.2012VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: pooled analysis of SAKK19/05 and NTR528
01.11.2012Lung Cancer 2012; 79:59-64
Gautschi Oliver, Stahel Rolf, Carbone David, Na Kyung-Jae, Hsu Schmitz Shu-Fang, Bubendorf Lukas, Baty Florent, Brutsche Martin, Pless Miklos, Zappa Francesco, Roder Joanna, Grigorieva Julia, Roder Heinrich, Peters Solange, Crowe Susanne, Dingemans Anne-Marie, Smit Egbert
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
Cathomas R, Gillessen Sommer S, von Moos R, Schiess R, Pless M, Berthold D, Siciliano D, Winterhalder R, Droege C, Cotting D, Brauchli P, Betticher D, Jaggi R, Bubendorf L, Klingbiel D, Rothermundt C, Swiss Group for Clinical Cancer Research SAKK. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07). Clin Cancer Res 2012; 18:6049-57.
12.09.2012Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07)
12.09.2012Clin Cancer Res 2012; 18:6049-57
Cathomas Richard, Gillessen Sommer Silke, von Moos Roger, Schiess Ralph, Pless Miklos, Berthold Dominik R, Siciliano Daniele, Winterhalder Ralph, Droege Cornelia, Cotting Denise, Brauchli Peter, Betticher Daniel C, Jaggi Rolf, Bubendorf Lukas, Klingbiel Dirk, Rothermundt Christian, Swiss Group for Clinical Cancer Research SAKK
Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
Früh M, Pless M, Fustier P, Küttel E, Simcock M, Rauch D, Krasniqi F, Erdmann A, Mamot C, Zippelius A, Tscherry G, Siano M, Cathomas R, Swiss Group for Clinical Cancer Research. Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2012; 14:34-9.
24.05.2012Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08)
24.05.2012Clin Lung Cancer 2012; 14:34-9
Früh Martin, Pless Miklos, Fustier Pierre, Küttel Erika, Simcock Mathew, Rauch Daniel, Krasniqi Fatima, Erdmann Andreas, Mamot Christoph, Zippelius Alfred, Tscherry Gregor, Siano Marco, Cathomas Richard, Swiss Group for Clinical Cancer Research
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
Pesce G, Bernhard J, Kotrubczik N, D'Addario G, Pilop C, Weber D, Bodis S, Pless M, Mayer M, Cathomas R, Peters S, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar C, Fischer N, Anchisi S, Stupp R. Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer 2011; 48:377-84.
15.11.2011Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03)
15.11.2011Eur J Cancer 2011; 48:377-84
Pesce Gianfranco A, Bernhard Jürg, Kotrubczik Nina M, D'Addario Giannicola, Pilop Christiane, Weber Damien C, Bodis Stephan, Pless Miklos, Mayer Michael, Cathomas Richard, Peters Solange, Klingbiel Dirk, Ribi Karin, Zouhair Abderahim, von Moos Roger, Schlaeppi Marc, Caspar Clemens B, Fischer Natalie, Anchisi Sandro, Stupp Roger
Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
Ruhstaller T, Brauchli P, Inauen R, Widmer L, Mingrone W, Gautschi O, Rauch D, Schneider P, Montemurro M, Moosmann P, von Moos R, Kranzbuehler H, Dietrich D, Pless M, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol 2011; 29:626-31.
04.01.2011Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06)
04.01.2011J Clin Oncol 2011; 29:626-31
Ruhstaller Thomas, Brauchli Peter, Inauen Roman, Widmer Lucas, Mingrone Walter, Gautschi Oliver, Rauch Daniel, Schneider Paul M, Montemurro Michael, Moosmann Peter, von Moos Roger, Kranzbuehler Helmut, Dietrich Daniel, Pless Miklos, Hess Viviane
Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer
Baty F, Tamm M, Kehren J, Buess M, Budach W, Marrer E, Savic S, Bubendorf L, Pless M, Schumacher M, Kaiser S, Facompre M, Brutsche M. Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer. American journal of respiratory and critical care medicine 2010; 181:181-8.
15.01.2010Gene profiling of clinical routine biopsies and prediction of survival in non-small cell lung cancer
15.01.2010American journal of respiratory and critical care medicine 2010; 181:181-8
Baty Florent, Tamm Michael, Kehren Jeanne, Buess Martin, Budach Wolfgang, Marrer Estelle, Savic Spasenija, Bubendorf Lukas, Pless Miklos, Schumacher Martin, Kaiser Sergio, Facompre Michael, Brutsche Martin
Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
Simcock M, Furrer H, Hirschel B, Vernazza P, Sendi P, Rickenbach M, Bucher H, Battegay M, Koller M, Moirandat-Rytz S, Terziroli B, Blasko M, Karrer U, Bertisch B, Pless M, Blumer L, Vora S, Robinson J, Bernasconi E, Swiss HIV Cohort Study. Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study. Antiviral therapy 2007; 12:931-9.
01.01.2007Treatment and prognosis of AIDS-related lymphoma in the era of highly active antiretroviral therapy: findings from the Swiss HIV Cohort Study
01.01.2007Antiviral therapy 2007; 12:931-9
Simcock Mathew, Furrer Hansjakob, Hirschel Bernard, Vernazza Pietro, Sendi Pedram, Rickenbach Martin, Bucher Heiner C, Battegay Manuel, Koller Michael T, Moirandat-Rytz Sophie, Terziroli Benedetta, Blasko Monika, Karrer Urs, Bertisch Barbara, Pless Miklos, Blumer Liisa, Vora Samir, Robinson James Owen, Bernasconi Enos, Swiss HIV Cohort Study
Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction
Chhajed P, Baty F, Pless M, Somandin S, Tamm M, Brutsche M. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction. Chest 2006; 130:1803-7.
01.12.2006Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction
01.12.2006Chest 2006; 130:1803-7
Chhajed Prashant N, Baty Florent, Pless Miklos, Somandin Stephanie, Tamm Michael, Brutsche Martin
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
Jermann M, Bauer J, Rhyner K, Egli F, Morant R, Gillessen Sommer S, Jörger M, Cerny T, Salzberg M, Stahel R, Pless M. A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer chemotherapy and pharmacology 2006; 57:533-9.
01.04.2006A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma
01.04.2006Cancer chemotherapy and pharmacology 2006; 57:533-9
Jermann Monika, Bauer Jean A, Rhyner Kaspar, Egli Fritz, Morant Rudolf, Gillessen Sommer Silke, Jörger Markus, Cerny Thomas, Salzberg Marc, Stahel Rolf A, Pless Miklos
Significant progress in palliative treatment of non-small cell lung cancer in the past decade
Waechter F, Passweg J, Tamm M, Brutsche M, Herrmann R, Pless M. Significant progress in palliative treatment of non-small cell lung cancer in the past decade. Chest 2005; 127:738-47.
01.03.2005Significant progress in palliative treatment of non-small cell lung cancer in the past decade
01.03.2005Chest 2005; 127:738-47
Waechter Frank, Passweg Jakob, Tamm Michael, Brutsche Martin, Herrmann Richard, Pless Miklos
Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
Betticher D, Stahel R, Weder W, Stupp R, Egli F, Furrer M, Honegger H, Wernli M, Cerny T, Spiliopoulos A, Roth A, Hsu Schmitz S, Tötsch M, Hansen E, Joss C, von Briel C, Schmid R, Pless M, Habicht J, Ris H. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9.
01.05.2003Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial
01.05.2003Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003; 21:1752-9
Betticher Daniel C, Stahel Rolf, Weder Walter, Stupp Roger, Egli Fritz, Furrer Markus, Honegger Hanspeter, Wernli Martin, Cerny Thomas, Spiliopoulos Anastase, Roth Arnaud D, Hsu Schmitz Shu-Fang, Tötsch Martin, Hansen Eva, Joss Christine, von Briel Christian, Schmid Ralph A, Pless Miklos, Habicht James, Ris Hans-Beat